Research Analysts Issue Forecasts for Incyte Co.’s FY2018 Earnings (INCY)

Incyte Co. (NASDAQ:INCY) – Analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for shares of Incyte in a research report issued on Thursday, Zacks Investment Research reports. Jefferies Group analyst B. Abrahams now forecasts that the biopharmaceutical company will post earnings of $1.18 per share for the year, down from their previous estimate of $1.28. Jefferies Group has a “Buy” rating and a $148.00 price objective on the stock.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 14th. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by $0.09. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The business had revenue of $326 million for the quarter, compared to analysts’ expectations of $324.90 million. During the same period last year, the business earned $0.29 earnings per share. The company’s quarterly revenue was up 33.9% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/04/21/fy2018-eps-estimates-for-incyte-co-incy-reduced-by-jefferies-group-updated.html.

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Several other equities analysts have also recently issued reports on INCY. Raymond James Financial, Inc. cut Incyte from an “outperform” rating to a “hold” rating in a report on Thursday, April 6th. Zacks Investment Research raised Incyte from a “sell” rating to a “hold” rating in a report on Tuesday. SunTrust Banks, Inc. decreased their price objective on Incyte from $160.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday. Gabelli assumed coverage on Incyte in a report on Monday, April 10th. They issued a “buy” rating and a $185.00 price objective for the company. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $149.00 price objective (up previously from $135.00) on shares of Incyte in a report on Thursday, February 16th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $139.40.

Incyte (NASDAQ:INCY) traded down 0.08% during midday trading on Friday, hitting $123.01. The company had a trading volume of 1,818,883 shares. Incyte has a 52 week low of $68.03 and a 52 week high of $153.15. The stock has a market capitalization of $23.30 billion, a PE ratio of 227.80 and a beta of 0.78. The stock has a 50 day moving average price of $138.77 and a 200-day moving average price of $114.39.

In other Incyte news, EVP Steven H. Stein sold 32,000 shares of the stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $137.88, for a total transaction of $4,412,160.00. Following the completion of the transaction, the executive vice president now owns 41,648 shares of the company’s stock, valued at $5,742,426.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 1,000 shares of Incyte stock in a transaction on Thursday, April 13th. The shares were purchased at an average cost of $139.66 per share, with a total value of $139,660.00. Following the acquisition, the director now directly owns 3,177 shares of the company’s stock, valued at $443,699.82. The disclosure for this purchase can be found here. Insiders have sold 127,571 shares of company stock valued at $18,145,772 in the last three months. Insiders own 13.70% of the company’s stock.

Several large investors have recently bought and sold shares of INCY. BlackRock Institutional Trust Company N.A. raised its stake in Incyte by 3.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,269,170 shares of the biopharmaceutical company’s stock worth $402,540,000 after buying an additional 125,739 shares during the period. BB Biotech AG raised its stake in Incyte by 1.0% in the third quarter. BB Biotech AG now owns 3,879,822 shares of the biopharmaceutical company’s stock worth $365,828,000 after buying an additional 39,416 shares during the period. Shelton Capital Management raised its stake in Incyte by 30,859.4% in the fourth quarter. Shelton Capital Management now owns 3,595,000 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,583,388 shares during the period. Franklin Resources Inc. raised its stake in Incyte by 5.6% in the fourth quarter. Franklin Resources Inc. now owns 2,959,613 shares of the biopharmaceutical company’s stock worth $296,778,000 after buying an additional 157,191 shares during the period. Finally, Norges Bank bought a new stake in Incyte during the fourth quarter worth about $180,561,000. Institutional investors and hedge funds own 92.62% of the company’s stock.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

5 Day Chart for NASDAQ:INCY

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply